TRxADE (NASDAQ: MEDS) today announced that its board of directors has declared a special cash dividend of $1.50 per share of common stock. According to the announcement, the special dividend is being paid using a portion of the proceeds received in May 2024 in connection with the prior sale of the company’s web-based market platform assets. The cash dividend is payable to stockholders of record as of July 19, 2024, with the dividend being paid on or about July 24, 2024.
To view the full press release, visit https://ibn.fm/FPbnT
About TRxADE Health Inc.
TRxADE Health is a parent company with various subsidiaries, which include the pharmaceutical marketplace https://rx.trxade.com and plant-based food https://superlatus.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
